Literature DB >> 9844931

Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.

M J Pongers-Willemse1, O J Verhagen, G J Tibbe, A J Wijkhuijs, V de Haas, E Roovers, C E van der Schoot, J J van Dongen.   

Abstract

Analysis of minimal residual disease (MRD) can predict outcome in acute lymphoblastic leukemia (ALL). A large prospective study in childhood ALL has shown that MRD analysis using immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements as PCR targets can identify good and poor prognosis groups of substantial size that might profit from treatment adaptation. This MRD-based risk group assignment was based on the kinetics of tumor reduction. Consequently, the level of MRD has to be defined precisely in follow-up samples. However, current PCR methods do not allow easy and accurate quantification. We have tested 'real-time' quantitative PCR (RQ-PCR) using the TaqMan technology and compared its sensitivity with two conventional MRD-PCR methods, ie dot-blot and liquid hybridization of PCR amplified Ig/TCR gene rearrangements using clone-specific radioactive probes. In RQ-PCR the generated specific PCR product is measured at each cycle ('real-time') by cleavage of a fluorogenic intrinsic TaqMan probe. The junctional regions of rearranged Ig/TCR genes define the specificity and sensitivity of PCR-based MRD detection in ALL and are generally used to design a patient-specific probe. In the TaqMan technology we have chosen for the same approach with the design of patient-specific TaqMan probes at the position of the junctional regions. We developed primers/probe combinations for RQ-PCR analysis of a total of three IGH, two TCRD, two TCRG and three IGK gene rearrangements in four randomly chosen precursor-B-ALL. In one patient, 12 bone marrow follow-up samples were analyzed for the presence of MRD using an IGK PCR target. The sensitivity of the RQ-PCR technique appeared to be comparable to the dot-blot method, but less sensitive than liquid hybridization. Although it still is a relatively expensive method, RQ-PCR allows sensitive, reproducible and quantitative MRD detection with a high throughput of samples providing possibilities for semi-automation. We consider this novel technique as an important step forward towards routinely performed diagnostic MRD studies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9844931     DOI: 10.1038/sj.leu.2401246

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  40 in total

1.  Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction.

Authors:  J L Slack; W Bi; K J Livak; N Beaubier; M Yu; M Clark; S H Kim; R E Gallagher; C L Willman
Journal:  J Mol Diagn       Date:  2001-11       Impact factor: 5.568

Review 2.  The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.

Authors:  J Moppett; G A A Burke; C G Steward; A Oakhill; N J Goulden
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

3.  An inexpensive gel electrophoresis-based polymerase chain reaction method for quantifying mRNA levels.

Authors:  William D Bradford; Laty Cahoon; Sara R Freel; Laura L Mays Hoopes; Todd T Eckdahl
Journal:  Cell Biol Educ       Date:  2005

4.  Real-time PCR method for the quantitative analysis of human T-cell receptor gamma and beta gene rearrangements.

Authors:  J L Chain; M L Joachims; S W Hooker; A B Laurent; C K Knott-Craig; L F Thompson
Journal:  J Immunol Methods       Date:  2005-03-18       Impact factor: 2.303

5.  Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes.

Authors:  Sa Deepak; Kr Kottapalli; R Rakwal; G Oros; Ks Rangappa; H Iwahashi; Y Masuo; Gk Agrawal
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

6.  Detailed analysis of Epstein-Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis.

Authors:  J Scherrenburg; E R W A N Piriou; N M Nanlohy; D van Baarle
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

7.  Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.

Authors:  Christiane Pott; Eva Hoster; Marie-Helene Delfau-Larue; Kheira Beldjord; Sebastian Böttcher; Vahid Asnafi; Anne Plonquet; Reiner Siebert; Evelyne Callet-Bauchu; Niels Andersen; Jacques J M van Dongen; Wolfram Klapper; Françoise Berger; Vincent Ribrag; Achiel L van Hoof; Marek Trneny; Jan Walewski; Peter Dreger; Michael Unterhalt; Wolfgang Hiddemann; Michael Kneba; Hanneke C Kluin-Nelemans; Olivier Hermine; Elizabeth Macintyre; Martin Dreyling
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

8.  CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties.

Authors:  Selim Kuçi; Zyrafete Kuçi; Hermann Kreyenberg; Erika Deak; Kathrin Pütsch; Sabine Huenecke; Chandrasekhar Amara; Stefanie Koller; Eva Rettinger; Manuel Grez; Ulrike Koehl; Hatixhe Latifi-Pupovci; Reinhard Henschler; Torsten Tonn; Dorothee von Laer; Thomas Klingebiel; Peter Bader
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

9.  Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).

Authors:  Hiroya Tamaki; Machiko Mishima; Manabu Kawakami; Akihiro Tsuboi; Eui Ho Kim; Naoki Hosen; Kazuhiro Ikegame; Masaki Murakami; Tatsuya Fujioka; Tomoki Masuda; Yuki Taniguchi; Sumiyuki Nishida; Kazuoki Osumi; Toshihiro Soma; Yusuke Oji; Yoshihiro Oka; Ichiro Kawase; Haruo Sugiyama; Hiroyasu Ogawa
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

10.  Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type.

Authors:  Yenlin Huang; Aurélien de Reyniès; Laurence de Leval; Bouchra Ghazi; Nadine Martin-Garcia; Marion Travert; Jacques Bosq; Josette Brière; Barbara Petit; Emilie Thomas; Paul Coppo; Teresa Marafioti; Jean-François Emile; Marie-Hélène Delfau-Larue; Christian Schmitt; Philippe Gaulard
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.